Invivyd falls after US FDA declines to expand emergency use of COVID-19 drug

Invivyd

24/02/2025 12:41

** Shares of drugmaker Invivyd  IVVD.O  fall 37.2% to $1.11
premarket
    ** Co says the U.S. FDA has declined to expand the emergency
use authorization of its COVID-19 prevention drug 
    ** The expansion was to include those whose immunity is
impaired by certain conditions such as cancer and organ
transplant, and for whom alternative options are not accessible
or appropriate
    ** The drug Pemgarda is already authorized for emergency use
in those with compromised immunity due to a medical condition or
receiving medicines that suppress the immune system, and
unlikely to have an adequate response to vaccination 
    ** IVVD fell 88.8% in 2024

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))